Marinus Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Marinus Pharmaceuticals generated cash of -$118,001,000, which is less than the previous year. Cash used in financing activities reached the amount of $26,627,000 last year. Net change in cash is therefore -$119,979,000.
Cash Flow
| 2014 | -8.58M | -33K | 48.30M |
|---|---|---|---|
| 2015 | -20.12M | -6.31M | 28.44M |
| 2016 | -24.76M | 1.39M | -2.17M |
| 2017 | -18.81M | -21.42M | 47.58M |
| 2018 | -27.84M | 19.91M | 42.12M |
| 2019 | -48.63M | 3.88M | 67.96M |
| 2020 | -60.91M | -738K | 109.21M |
| 2021 | -55.47M | -1.41M | 41.31M |
| 2022 | -112.88M | 105.77M | 124.73M |
| 2023 | -118.00M | -28.60M | 26.62M |
MRNS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 240.55M | 122.92M | 138.50M | 90.94M | 67.72M | 33.53M | 26.17M | 51.72M | 49.72M | 10.03M |
Operating activities | ||||||||||
Net income | -141.40M | -19.81M | -98.77M | -67.47M | -54.12M | -36.72M | -18.89M | -28.64M | -24.85M | -10.83M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 551K | 418K | 355K | 334K | 278K | 127K | 126K | 23K | 11K | 5K |
Stock-based compensation expense | 15.56M | 14.89M | 13.86M | 7.64M | 5.67M | 0 | 2.88M | 3.07M | 2.10M | 698K |
| Deferred income tax benefit | 15.56M | 14.89M | 13.86M | 7.64M | 5.67M | 0 | 2.88M | 3.07M | 2.10M | 698K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 2.61M | -5.57M | -853K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 853K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 2.10M | 3.75M | 7.84M | 1.87M | 890K | -2.12M | -2.12M | -629K | 3.54M | 1.38M |
Cash generated by operating activities | -118.00M | -112.88M | -55.47M | -60.91M | -48.63M | -27.84M | -18.81M | -24.76M | -20.12M | -8.58M |
Investing activities | ||||||||||
Purchases Of Investments | -51.99M | -171K | 0 | -8.93M | -2.72M | -24.89M | -24.89M | -2.43M | -7.70M | 0 |
Investments In Property Plant And Equipment | -119K | -1.77M | -2.88M | 0 | -388K | -83K | -450K | -644K | -352K | -33K |
Acquisitions Net | 0 | 171K | 0 | 0 | -4.26M | 0 | 0 | 0 | 352K | 0 |
Cash generated by investing activities | -28.60M | 105.77M | -1.41M | -738K | 3.88M | 19.91M | -21.42M | 1.39M | -6.31M | -33K |
Financing activities | ||||||||||
Common Stock Issued | 25.82M | 64.47M | 1.19M | 108.19M | 67.87M | 0 | 52.54M | 0 | 0 | 41.20M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 58.50M | -40.11M | 0 | 0 | -193K | -5.05M | -2.12M | 28.27M | 0 |
Cash used in financing activities | 26.62M | 124.73M | 41.31M | 109.21M | 67.96M | 42.12M | 47.58M | -2.17M | 28.44M | 48.30M |
Net Change In Cash | -119.97M | 117.62M | -15.58M | 47.56M | 23.21M | 34.19M | 7.35M | -25.54M | 2.00M | 39.68M |
Cash at end of period | 120.57M | 240.55M | 122.92M | 138.50M | 90.94M | 67.72M | 33.53M | 26.17M | 51.72M | 49.72M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |